CBD (cannabidiol) has become a popular tool for supporting neurological symptoms—especially seizures, anxiety, and nervous system dysregulation. It works primarily by influencing the endocannabinoid system (ECS), which helps regulate mood, inflammation, and brain signaling.
But what happens when CBD doesn’t help?
This is more common than people think—and it often provides an important clue:
the root issue may not be centered in the endocannabinoid system at all.
What CBD Is Actually Doing
CBD works indirectly by:
- Increasing endocannabinoids like anandamide
- Modulating serotonin (5-HT1A receptors)
- Reducing inflammation
- Stabilizing calcium flow in brain cells
(Ibeas Bih et al., Neurotherapeutics, 2015)
This means CBD is most helpful when symptoms are driven by:
- Inflammation
- Stress signaling
- ECS imbalance
If those aren’t the primary drivers, results may be limited.
When CBD Falls Short: A Functional Perspective
In functional medicine, we often see that neurological symptoms are influenced by multiple overlapping systems:
- Neurotransmitter imbalances
- Toxic burden (mold, chemicals, heavy metals)
- Nutrient deficiencies
- Gut dysfunction
If these are the root causes, CBD alone won’t resolve the issue.
The GABA Pathway: The Missing Piece for Many
One of the most important pathways to evaluate is GABA, the brain’s primary calming neurotransmitter.
When GABA is low or not functioning properly, the brain becomes overstimulated. This can present as:
- Seizures
- Anxiety or panic
- Sensory sensitivity
- Sleep disruption
CBD may help slightly—but it does not strongly correct GABA deficiencies.
Functional support for GABA may include:
- Magnesium (critical for calming NMDA activity)
- Vitamin B6 (P5P) for GABA synthesis
- Glycine and taurine
- L-theanine
(Möhler H., Pharmacol Rev, 2012)
Glutamate: When the Brain Is “Stuck On”
Glutamate is the main excitatory neurotransmitter. When levels are too high, the brain can become overstimulated and even neurotoxic.
This is commonly seen in:
- OAT markers like elevated quinolinic acid or 3-oxoglutaric acid
- Mold toxicity (e.g., ochratoxin A)
- Inflammatory states
CBD has only mild effects here.
Support strategies may include:
- Magnesium (NMDA receptor regulation)
- NAC (supports glutathione and glutamate balance)
- Omega-3 fatty acids
(Lewerenz & Maher, Front Neurosci, 2015)
Toxins: A Major Root Cause Often Overlooked
In your clinical framework, this is often where the story begins.
Toxins such as:
- MTBE, styrene
- Mycotoxins (like ochratoxin A)
can disrupt:
- Neurotransmitter signaling
- Mitochondrial energy production
- Mineral balance
When toxins are driving dysfunction, the nervous system stays dysregulated—no matter how much CBD is used.
Support focus may include:
- Binders (gentle and individualized)
- Glutathione support
- Liver detox pathways
Minerals: The Foundation of Brain Stability
Minerals are essential for proper neurotransmitter function.
Common patterns we see:
- Low magnesium → increased excitability
- Zinc/copper imbalance → mood and neurological instability
- Low trace minerals → poor enzyme function
Without correcting these, neurotransmitter therapies often don’t “stick.”
Mitochondria: The Energy Behind the Brain
The brain is energy-intensive. If mitochondrial function is impaired, symptoms can include:
- Fatigue
- Brain fog
- Poor stress tolerance
- Neurological instability
CBD does not address this directly.
Support may include:
- CoQ10
- Carnitine
- B vitamins
Bringing It All Together
CBD can be helpful—but it’s just one piece of a much larger puzzle.
When it doesn’t work, it’s often a sign to look deeper:
- Is GABA support needed?
- Is glutamate too high?
- Are toxins interfering with signaling?
- Are minerals depleted?
- Is cellular energy compromised?
By addressing these foundational systems, we often see more meaningful and lasting improvements than focusing on the endocannabinoid system alone.
Bringing much light,
Lynn
References
- Ibeas Bih C. et al. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics
- Möhler H. (2012). The GABA system in anxiety and depression. Pharmacol Rev
- Lewerenz J, Maher P. (2015). Chronic glutamate toxicity. Front Neurosci
